natgillin/translations-raw huggingface dataset:
Mifamurtide was studied as a single agent in 248 patients with mostly advanced malignancies during the early, single arm phase I and II clinical studies. 
Mifamurtid so raziskovali kot samostojno zdravilo pri 248 bolnikih z večinoma napredovalimi malignimi novotvorbami v zgodnjih enoskupinskih kliničnih študijah I. in II.
MEPACT is then infused directly into your vein (intravenous) over about 1 hour. 
Zdravilo MEPACT se nato infundira neposredno v veno (intravensko) približno 1 uro.
Activation of human macrophages by mifamurtide is associated with production of cytokines, including tumour necrosis factor (TNF-), interleukin-1 (IL-1), IL-6, IL-8, and IL-12 and adhesion molecules, including lymphocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1). 
Aktivacija človeških makrofagov z mifamurtidom je povezana s produkcijo citokinov, vključno s faktorjem tumorske nekroze (TNF-), interlevkinom-1 (IL-1), IL-6, IL-8 in IL-12, ter adhezijskih molekul, ki zajemajo z delovanjem limfocita povezan antigen-1 (LFA-1) in intercelularno adhezijsko molekulo-1 (ICAM-1).
For further instructions on reconstitution, filtering using the filter provided and dilution of the medicinal product before administration, see section 6.6. 
Za dodatna navodila glede rekonstitucije, filtriranja s priloženim filtrom in redčenja zdravila pred uporabo glejte poglavje 6.6.
You should not stop treatment with MEPACT before finishing the course of treatment without discussing with your doctor first. 
Predvidenega poteka zdravljenja z zdravilom MEPACT ne smete prekiniti ne da bi se prej o tem posvetovali z zdravnikom.
Gastrointestinal toxicity may be exacerbated when mifamurtide is used in combination with high dose, multi-agent chemotherapy and was associated with an increased use of parenteral nutrition. 
Gastrointestinalna toksičnost se lahko poslabša, če se mifamurtid uporablja v kombinaciji s polikemoterapijo v visokih odmerkih in je bila povezana s pogostejšo uporabo parenteralne prehrane.
• 1 single use 60 or 100 mL sterile syringe with luer lock 
• 1 60- ali 100-ml sterilna injekcijska brizga za enkratno uporabo z luer lock nastavkom
In a randomised phase III study of 678 patients (age range from 1.4 to 30.6 years) with newly-diagnosed resectable high-grade osteosarcoma, the addition of adjuvant mifamurtide to chemotherapy (either doxorubicin cisplatin and methotrexate with or without ifosfamide), significantly increased the 6-year overall survival and resulted in a relative reduction in the risk of death by 28% (p = 0.0313, hazard ratio (HR) = 0.72 [95% confidence interval (CI): 0.53, 0. 
V randomizirani študiji III. faze, v kateri je sodelovalo 678 bolnikov (starih od 1,4 do 30,6 let) z novo diagnosticiranim operabilnim osteosarkomom visoke stopnje, je dodajanje mifamurtida kot adjuvanta kemoterapiji (z doksorubicinom ali cisplatinom in metotreksatom z ali brez ifosfamida) v veliki meri povečalo 6-letno skupno preživetje in povzročilo relativno zmanjšanje tveganja za smrt za 28% (p = 0,0313, razmerje tveganja (HR) = 0,72 [95% interval zaupanja (CI): 0,53, 0,97]).
During mifamurtide administration, patients should be monitored for unusual signs or symptoms, such as arthritis or synovitis, suggestive of uncontrolled inflammatory reactions. 
Med uporabo mifamurtida je treba bolnike nadzirati glede pojava neobičajnih znakov ali simptomov, kot sta artritis ali sinovitis, ki kažejo na nenadzorovane vnetne reakcije.
Pharmacokinetic variability was higher in the moderate hepatic impairment group (co-efficient of variation in systemic exposure [AUCinf] was 50% versus < 30% in the other hepatic function groups). 
V skupini z zmerno okvaro jeter je bila variabilnost farmakokinetike večja (koeficient variacije sistemske izpostavljenosti [AUCinf] je znašal 50% v primerjavi z < 30% v skupinah z drugačnim delovanjem jeter).
because this may be a sign of an infection, or - if you experience rash or have any problems breathing (wheezing), or - if you experience any stomach problems. 
MEPACT, saj je to lahko znak okužbe, - če dobite izpuščaj ali imate težave z dihanjem (piskanje), ali - če imate kakršne koli prebavne težave.
- ciclosporin, tacrolimus, used after a transplant to prevent rejection of transplanted organs, or other immunosuppressants used e.g. to treat psoriasis (a skin disease). 
- ciklosporin, takrolimus, ki se uporabljata po presaditvi za preprečitev zavrnitve presajenih organov, ali druga zdravila za zaviranje imunske odzivnosti, ki se uporabljajo, na primer, za zdravljenje psoriaze (kožna bolezen).
The desired dose may be withdrawn from the vial by inverting the vial and slowly pulling back on the syringe plunger (figure 3). 
Želeni odmerek lahko iz viale odmerite tako, da vialo obrnete in počasi potegnete bat brizge navzdol (slika 3).
The recommended dose of mifamurtide for all patients is 2 mg/m body surface area. 
Priporočeni odmerek mifamurtida za vse bolnike je 2 mg/m2 telesne površine.
Examples include paracetamol for fever, chills and headache and anti-emetics (other than steroids) for nausea and vomiting. 
Med njimi so, na primer, paracetamol za zvišano telesno temperaturo, mrzlico in glavobol ter antiemetiki (razen steroidov) za navzeo in bruhanje.
Paediatric population < 2 years 
Pediatrična populacija, mlajša od 2 let
Embryotoxic effects were observed only at maternal toxic levels. 
Embriotoksične učinke so opazili samo pri koncentraciji, toksični za mater.
It is used in combination with post-operative multi-agent chemotherapy. 
Uporablja se v kombinaciji s pooperativno polikemoterapijo.
Haemorrhage was observed in animals at very high doses. 
Pri živalih so se pri zelo visokih odmerkih pojavile krvavitve.
Because mifamurtide acts through stimulation of the immune system, the chronic or routine use of corticosteroids should be avoided during treatment with mifamurtide. 
Ker mifamurtid deluje prek stimulacije imunskega sistema, se je med zdravljenjem z mifamurtidom treba izogibati kronični ali rutinski uporabi kortikosteroidov.
- Non-steroidal-anti-inflammatory drugs (NSAIDs), such as acetylsalicylic acid, ibuprofen, or diclofenac, used for treatment of headaches, fever or pain. 
- nesteroidna protivnetna zdravila (NSAIDs), kot so acetilsalicilna kislina, ibuprofen ali diklofenak, ki se uporabljajo za zdravljenje glavobolov, zvišane telesne temperature ali bolečine.
Many of the very commonly reported adverse reactions as shown in the following summary table are thought to be related to the mechanism of action of mifamurtide (see table 1). 
Večina zelo pogostih neželenih učinkov, ki so prikazani v spodnji zbirni preglednici, naj bi bila povezana z mehanizmom delovanja mifamurtida (glejte preglednico 1).
MEPACT must not be administered as a bolus injection. 
Zdravila MEPACT se ne sme uporabljati v obliki bolus injekcije.
Data from a six-month dog study of daily intravenous injections of up to 0.5 mg/kg (10 mg/m mifamurtide provide an 8- to 19-fold cumulative exposure safety margin for overt toxicity for the intended clinical dose in humans. 
Podatki iz šestmesečne študije pri psih z intravenskimi injekcijami mifamurtida v odmerku do 0,5 mg/kg (10 mg/m2) na dan kažejo 8- do 19-kratno kumulativno varno mejo izpostavljenosti za očitno toksičnost predvidenega kliničnega odmerka pri ljudeh.
Store in a refrigerator (2 C-8 °C). 
Shranjujte v hladilniku (2 C - 8 °C).
Materials required but not provided 
Potrebni materiali, ki niso priloženi
Liposomal and non-liposomal mifamurtide do not induce the metabolic activity or the transcription of cytochrome P450 in primary cultures of freshly isolated human hepatocytes. 
Liposomski in neliposomski mifamurtid ne inducira presnovne aktivnosti ali transkripcije citokroma P450 v primarnih kulturah sveže izoliranih človeških hepatocitov.
Not known (cannot be estimated from the available data): - abnormal accumulation of fluid around the heart (pericardial effusion) 
Neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov) - nabiranje tekočine v osrčniku (perikardialni izliv)
The following events were also observed: haemorrhage and prolongation of coagulation times, infarcts, morphological changes in the wall of small arteries, oedema and congestion of the central nervous system, minor cardiac effects, and slight hyponatraemia. 
Opaženi so bili tudi naslednji dogodki: krvavitev in podaljšanje časov strjevanja krvi, infarkti, morfološke spremembe v steni majhnih arterij, edem in kongestija osrednjega živčnega sistema, manjši učinki na srce in blaga hiponatriemija.
Frequency category Adverse reaction (preferred term) 
Neželeni učinek (prednostni izraz)
Therefore, MEPACT should not be used during pregnancy and in women of childbearing potential not using effective contraception. 
Zdravilo MEPACT se zato ne sme uporabljati med nosečnostjo in pri ženskah v rodni dobi, ki ne uporabljajo učinkovite kontracepcije.
Nausea, vomiting and loss of appetite are very common adverse reactions to mifamurtide (see section 4.8). 
Navzea, bruhanje in izguba apetita so zelo pogosti neželeni učinki mifamurtida (glejte poglavje 4.8).
It is not known whether MEPACT passes to human milk. 
Ni znano, če zdravilo MEPACT prehaja v materino mleko.
The use of mifamurtide concurrently with ciclosporin or other calcineurin inhibitors is contraindicated due to their hypothesised effect on splenic macrophages and mononuclear phagocytic function (see section 4.3). 
Uporaba mifamurtida skupaj s ciklosporinom ali z drugimi zaviralci kalcinevrina je kontraindicirana zaradi njihovega domnevnega vpliva na makrofage v vranici ali funkcijo mononuklearnih fagocitov (glejte poglavje 4.3).
These are typically mild to moderate, transient in nature and generally respond to palliative treatment (e.g., paracetamol for fever). 
Navadno so blage do zmerne, prehodne narave in se na splošno odzivajo na paliativno zdravljenje (npr. paracetamol za zvišano telesno temperaturo).
Based on the prevalence of the disease, children and young adults were studied in the pivotal trial. 
Otroke in mlajše odrasle so na podlagi razširjenosti bolezni proučevali v ključnem preskušanju.
What MEPACT is and what it is used for What you need to know before you use MEPACT How to use MEPACT 
Kaj je zdravilo MEPACT in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo MEPACT Kako uporabljati zdravilo MEPACT Možni neželeni učinki
The reconstituted, filtered and diluted suspension for infusion is a homogenous, white to off-white, opaque liposomal suspension, free of visible particles and free of foam and lipid lumps. 
Rekonstituirana, filtrirana in razredčena suspenzija za infundiranje je homogena, bela do umazano bela, neprozorna liposomska suspenzija, ki ne vsebuje vidnih delcev, pene in lipidnih gmot.
After removing the needle from the syringe, the syringe should be attached to the filter by opening the filter luer connector cap (figure 1). 
Ko iglo snamete z brizge, morate slednjo pritrditi na filter, tako da odprete pokrovček filtrskega luer nastavka (slika 1).
These are not expected at the recommended dose, however monitoring of clotting parameters after the first dose and once again after several doses is recommended. 
Krvavitve pri priporočenem odmerku niso pričakovane, vendar pa je po prvem odmerku priporočljivo preveriti parametre strjevanja krvi in preiskavo po naslednjih nekaj odmerkih ponoviti.
Mifamurtide may be given during periods of neutropenia, but subsequent fever attributed to the treatment should be monitored closely. 
Mifamurtid se lahko uporablja v obdobjih nevtropenije, posledično zvišano telesno temperaturo, pripisano zdravljenju, pa je treba skrbno nadzirati.
Chemical and physical in-use stability has been demonstrated for 6 hours at room temperature (between approximately 20 C-25 °C). 
Ugotovljena je bila kemijska in fizikalna stabilnost pripravljene suspenzije 6 ur pri sobni temperaturi (med približno 20 C - 25 °C).
The maximum tolerated dose in phase I studies was 4-6 mg/m with a high variability of adverse reactions. 
Največji še toleriran odmerek v študijah I. faze je bil 4-6 mg/m2 z zelo različnimi neželenimi učinki.
In patients with a history of asthma or other chronic obstructive pulmonary disease, consideration should be given to administration of bronchodilators on a prophylactic basis. 
Pri bolniki z astmo ali drugo kronično obstruktivno pljučno boleznijo v anamnezi je treba razmisliti o profilaktični uporabi bronhodilatatorjev.
Each carton contains 1 vial and 1 single-use, non-pyrogenic, sterile filter for MEPACT supplied in a PVC-grade blister. 
Ena škatla vsebuje 1 vialo in 1 nepirogeni sterilni filter za enkratno uporabo za zdravilo MEPACT, ki je priložen v PVC pretisnem omotu.
Talk to your doctor before using MEPACT: if you have or have had problems with your heart or blood vessels, like blood clots (thrombosis), bleeding (haemorrhage) or inflammation of the veins (vasculitis). 
Pred začetkom uporabe zdravila MEPACT se posvetujte z zdravnikom: - če imate ali ste kdaj imeli težave s srcem ali ožiljem, na primer krvne strdke (tromboza), krvavitve (hemoragija) ali vnetje žil (vaskulitis).
All patients received a total dose of cisplatin of 480 mg/m2 as part of their induction (neoadjuvant) and/or maintenance (adjuvant) chemotherapy regimen. 
Vsi bolniki so prejeli skupni odmerek cisplatina 480 mg/m2 v sklopu njihovega začetnega (neoadjuvantnega) in/ali vzdrževalnega
Therefore, the use of high-dose NSAIDs is contraindicated (see section 4.3). 
Zato je uporaba visokih odmerkov nesteroidnih protivnetnih zdravil kontraindicirana (glejte poglavje 4.3).
if you develop chills or shivering, or feel warm. 
- če se pojavi mrzlica, tresenje ali čutite vročino.
One serious incident of subacute thrombosis was reported in early studies, but no serious cardiac events were associated with mifamurtide in a large randomised controlled study (see section 4.4). 
V zgodnjih študijah so poročali o enem resnem primeru subakutne tromboze, v obsežni randomizirani nadzorovani študiji pa z mifamurtidom niso bili povezani nobeni resni srčni dogodki (glejte poglavje 4.4).
After injection of radiolabelled liposomes containing mifamurtide, mean half-life of radiolabelled material was biphasic with an α-phase of about 15 minutes and a terminal half-life of approximately 18 hours. 
Po injiciranju z radioaktivnim izotopom označenih liposomov, ki so vsebovali mifamurtid, je bil povprečni razpolovni čas z radioaktivnim izotopom označenega materiala dvofazen, pri čemer je α-faza trajala približno 15 minut, končni razpolovni čas pa približno 18 ur.
Metabolism of liposomal MTP-PE has not been studied in humans. 
Presnove liposomskega MTP-PE pri človeku niso raziskovali.
MEPACT is a liposomal formulation specifically designed for in vivo targeting to macrophages by intravenous infusion. 
Zdravilo MEPACT je liposomska formulacija, posebej zasnovana za in vivo ciljanje makrofagov z intravensko infuzijo.
Like all medicines, MEPACT can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
How to use MEPACT 
Kako uporabljati zdravilo MEPACT
This medicine contains less than 1 mmol sodium (23 mg) per dosage unit. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na enoto odmerka.
See section 2 “MEPACT contains sodium” 
Glejte poglavje 2 Zdravilo MEPACT vsebuje natrij
It is unknown whether mifamurtide is excreted in human milk. 
Ni znano, če se mifamurtid izloča v materino mleko.
However, as the variability in pharmacokinetics of mifamurtide is greater in subjects with moderate hepatic impairment (see section 5.2), and safety data in patients with moderate hepatic impairment is limited, caution when administering mifamurtide to patients with moderate hepatic impairment is recommended. 
Ker pa je pri osebah z zmerno okvaro jeter variabilnost farmakokinetike mifamurtida večja (glejte poglavje 5.2), podatki o varnosti pri bolnikih z zmerno okvaro jeter pa omejeni, je pri bolnikih z zmerno okvaro jeter treba mifamurtid vseeno uporabljati previdno.
From a microbiological point of view, immediate use is recommended. 
Z mikrobiološkega stališča je priporočljivo, da zdravilo uporabite takoj.
The PIL should be updated accordingly. 
Navodilo za uporabo je treba ustrezno posodobiti.
Before using MEPACT, you should discuss with your doctor whether you should take medicine for your asthma when using MEPACT. 
Pred uporabo zdravila MEPACT se posvetujte z zdravnikom, če morate med zdravljenjem z zdravilom MEPACT jemati zdravilo za zdravljenje astme.
At 6 hours after injection of radiolabelled liposomes containing 1 mg mifamurtide, radioactivity was found in liver, spleen, nasopharynx, thyroid, and, to a lesser extent, in lung. 
Šest ur po injiciranju z radioaktivnim izotopom označenih liposomov, ki so vsebovali 1 mg mifamurtida, je bila radioaktivnost zaznana v jetrih, vranici, nazofarinksu, ščitnici in v manjši meri v pljučih.
Once reconstituted in sodium chloride 9 mg/mL (0.9%) solution, store at room temperature (approximately 20ºC - 25ºC) and use within 6 hours. 
Rekonstituirano suspenzijo v raztopini natrijevega klorida 9 mg/ml (0,9%) hranite pri sobni temperaturi (približno 20 ºC - 25 ºC) in porabite v 6 urah.
In vitro-treated human monocytes killed allogeneic and autologous tumour cells (including melanoma, ovarian, colon, and renal carcinoma), but had no toxicity towards normal cells. 
Človeški monociti, obravnavani in vitro, so uničili alogenske in avtologne tumorske celice (vključno z melanomom, ovarijskim karcinomom, karcinomom kolona in ledvičnim karcinomom), niso pa bili toksični za normalne celice.
In 28 osteosarcoma patients aged 6 to 39 years serum total (liposomal and free) mifamurtide concentrations declined rapidly with a mean half-life of 2.04 ± 0.456 hours. 
Pri 28 bolnikih z osteosarkomom, starih od 6 do 39 let, so se koncentracije skupnega mifamurtida (liposomskega in prostega) v serumu hitro zmanjševale s povprečnim razpolovnim časom 2,04 ± 0,456 ure.
Limited studies of the interaction of mifamurtide with chemotherapy have been conducted. 
Izvedenih je bilo le nekaj študij o medsebojnem delovanju mifamurtida s kemoterapijo.
If you have long-lasting or worsening symptoms, you should contact your doctor, as MEPACT treatment may need to be delayed or discontinued. 
Če imate dolgotrajne simptome ali simptome, ki se slabšajo, o tem obvestite zdravnika, saj bo zdravljenje z zdravilom MEPACT morda treba preložiti ali prekiniti.
If not used immediately, the reconstituted, filtered and diluted solution in-use storage times and conditions prior to use of the reconstituted product must not be longer than 6 hours at 25 ºC. 
Če ni uporabljeno takoj, čas shranjevanja rekonstituirane, filtrirane in razredčene, za uporabo pripravljene suspenzije pred uporabo rekonstituiranega zdravila ne sme preseči 6 ur pri temperaturi 25 °C.
Major toxic effects associated with these high daily and cumulative doses of mifamurtide were mainly exaggerated pharmacological effects: pyrexia, signs of pronounced inflammatory response manifested as synovitis, bronchopneumonia, pericarditis and inflammatory necrosis of the liver and bone marrow. 
Glavni toksični učinki, povezani s temi visokimi dnevnimi odmerki in kumulativnimi odmerki mifamurtida, so bili predvsem poudarjeni farmakološki učinki: pireksija, znaki izrazitega vnetnega odziva v obliki sinovitisa, bronhopnevmonije, perikarditisa in vnetne nekroze jeter in kostnega mozga.
There was no effect of mild hepatic impairment on the systemic exposure (AUCinf) of total MTP-PE. 
Blaga okvara jeter ni imela nobenega vpliva na sistemsko izpostavljenost (AUCinf) skupnemu MTP-PE.
Occasional allergic reactions have been associated with mifamurtide treatment, including rash, shortness of breath and grade 4 hypertension (see section 4.8). 
Zdravljenje z mifamurtidom je bilo občasno povezano s pojavom alergijskih reakcij, vključno z izpuščajem, zasoplostjo in hipertenzijo 4. stopnje (glejte poglavje 4.8).
One patient in the phase III study experienced 2 episodes of grade 4 seizure while on study therapy with chemotherapy and mifamurtide. 
Pri enem bolniku v študiji III. faze sta pri zdravljenju s kemoterapijo in z mifamurtidom pojavila 2 epizodi epileptičnih napadov 4. stopnje.
This medicine contains less than 1 mmol sodium (23 mg) per dosage unit, that is to say essentially ‘sodium-free'. 
To zdravilo vsebuje manj kot 1 mmol (23 mg) natrija na enoto odmerka, kar v bistvu pomeni "brez natrija".
Dizziness, vertigo, fatigue and blurred vision have shown as very common or common undesirable effects of mifamurtide treatment. 
Izkazalo se je, da so omotica, vrtoglavica, utrujenost in zamegljen vid zelo pogosti ali pogosti neželeni učinki mifamurtida.
• 1 Filter for MEPACT 
• 1 filter za zdravilo MEPACT
It is recommended that the reconstitution of the liposomal suspension should be performed in a laminar flow cabinet utilising sterile gloves using aseptic technique. 
Priporočljivo je, da rekonstitucijo liposomske suspenzije opravite v komori z laminarnim pretokom zraka z uporabo sterilnih rokavic in z aseptično tehniko.
The recommended dose of MEPACT is 2 mg mifamurtide/m body surface area. 
Priporočeni odmerek zdravila MEPACT je 2 mg mifamurtida/m2 telesne površine.
• Sodium chloride 9 mg/mL (0.9%) solution for injection, 100 mL bag 
• raztopina natrijevega klorida 9 mg/ml (0,9%) za injiciranje, 100 ml vrečka
Moderate hepatic impairment resulted in a small increase in AUCinf of total MTP-PE, with the geometric least square mean ratio (expressed as %) for moderate hepatic impairment in reference to the matched normal hepatic function group being 119% (90% confidence interval [CI]: 94.1%-151%). 
Zmerna okvara jeter je povzročila majhno povečanje AUCinf skupnemu MTP-PE, pri čemer je razmerje geometrijskih srednjih vrednosti najmanjših kvadratov (izraženo v%) pri zmerni okvari jeter v primerjavi s primerljivo skupino z normalnim delovanjem jeter znašalo 119% (90% interval zaupanja [IZ]: 94,1%-151%).
Association of mifamurtide with signs of pronounced inflammatory response, including pericarditis and pleuritis, was uncommon. 
Mifamurtid je bil občasno povezan z znaki poudarjenega vnetnega odziva, vključno s perikarditisom in plevritisom.
Episodes of neutropenic fever should be monitored and managed appropriately. 
Epizode nevtropenije z zvišano telesno temperaturo je treba nadzirati in ustrezno zdraviti.
There was also one report of a grade 4 allergic reaction (hypertension) requiring hospitalization in the phase III study (see section 4.4). 
Tudi v študiji III. faze so poročali o enem primeru alergijske reakcije 4. stopnje (hipertenzija), zaradi katere je bilo treba bolnika sprejeti in zdraviti v bolnišnici (glejte poglavje 4.4).
In a large controlled randomised study, mifamurtide used at the recommended dose and schedule with other medicinal products that have known renal (cisplatin, ifosfamide) or hepatic (high-dose methotrexate, ifosfamide) toxicities did not exacerbate those toxicities and there was no need to adjust mifamurtide dose. 
V obsežni nadzorovani randomizirani študiji se pri uporabi mifamurtida v priporočenem odmerku in režimu odmerjanja skupaj z drugimi zdravili, za katera je znano, da so toksična za ledvice (cisplatin, ifosfamid) ali jetra (visok odmerek metotreksata, ifosfamid), toksičnost ni povečala, odmerka mifamurtida pa ni bilo treba prilagajati.
- if you are taking medicines containing ciclosporin or other calcineurin inhibitors or high doses of non-steroidal-anti-inflammatory drugs (NSAIDs) (see “Using other medicines” below). 
- če jemljete zdravila, ki vsebujejo ciklosporin ali druge zaviralce kalcinevrina ali velike odmerke nesteroidnih protivnetnih zdravil (glejte “Druga zdravila in zdravilo MEPACT” v nadaljevanju).
In 21 healthy adult subjects mifamurtide was cleared rapidly from serum (minutes) with a half-life of 2.05 ± 0.40 hours, resulting in a very low serum concentration of total (liposomal and free) mifamurtide. 
Pri 21 zdravih odraslih preiskovancih se je mifamurtid hitro očistil iz seruma (minute) z razpolovnim časom 2,05 ± 0,40 ure, zato je bila koncentracija skupnega mifamurtida (liposomskega in prostega) v serumu zelo nizka.